This study is a double-blinded randomized-controlled trial in which patients will be
randomized to 81 mg of aspirin or placebo to be continued for 6 weeks' postpartum. The
purpose of this study is to compare NT-proBNP levels at the 4-6 week postpartum visit between
groups. There is currently no data on the maternal health effects associated with
continuation of low-dose aspirin in the postpartum period. This study aims to fill a gap in
the knowledge regarding the utility of low-dose aspirin following delivery.